Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.21
EXEL's Cash to Debt is ranked lower than
93% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. EXEL: 0.21 )
Ranked among companies with meaningful Cash to Debt only.
EXEL' s 10-Year Cash to Debt Range
Min: 0.21  Med: 1.45 Max: N/A
Current: 0.21
Equity to Asset -0.76
EXEL's Equity to Asset is ranked lower than
97% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. EXEL: -0.76 )
Ranked among companies with meaningful Equity to Asset only.
EXEL' s 10-Year Equity to Asset Range
Min: -0.76  Med: 0.14 Max: 0.8
Current: -0.76
-0.76
0.8
F-Score: 4
Z-Score: -10.23
M-Score: -2.85
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -489.37
EXEL's Operating margin (%) is ranked lower than
71% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. EXEL: -489.37 )
Ranked among companies with meaningful Operating margin (%) only.
EXEL' s 10-Year Operating margin (%) Range
Min: -893.86  Med: -179.05 Max: 30.91
Current: -489.37
-893.86
30.91
Net-margin (%) -641.58
EXEL's Net-margin (%) is ranked lower than
75% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. EXEL: -641.58 )
Ranked among companies with meaningful Net-margin (%) only.
EXEL' s 10-Year Net-margin (%) Range
Min: -1069.42  Med: -178.10 Max: 26.14
Current: -641.58
-1069.42
26.14
ROA (%) -59.10
EXEL's ROA (%) is ranked lower than
73% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. EXEL: -59.10 )
Ranked among companies with meaningful ROA (%) only.
EXEL' s 10-Year ROA (%) Range
Min: -134.14  Med: -27.54 Max: 20.08
Current: -59.1
-134.14
20.08
ROC (Joel Greenblatt) (%) -5603.46
EXEL's ROC (Joel Greenblatt) (%) is ranked lower than
79% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. EXEL: -5603.46 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
EXEL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5996.1  Med: -377.97 Max: 766.96
Current: -5603.46
-5996.1
766.96
Revenue Growth (3Y)(%) -61.20
EXEL's Revenue Growth (3Y)(%) is ranked lower than
86% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. EXEL: -61.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
EXEL' s 10-Year Revenue Growth (3Y)(%) Range
Min: -61.2  Med: 2.45 Max: 25.6
Current: -61.2
-61.2
25.6
» EXEL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

EXEL Guru Trades in Q3 2014

Paul Tudor Jones 28,200 sh (New)
Jim Simons Sold Out
» More
Q4 2014

EXEL Guru Trades in Q4 2014

Jim Simons 178,033 sh (New)
Paul Tudor Jones Sold Out
» More
Q1 2015

EXEL Guru Trades in Q1 2015

John Burbank 78,200 sh (unchged)
Jim Simons Sold Out
» More
Q2 2015

EXEL Guru Trades in Q2 2015

Charles Brandes 25,400 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with EXEL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 35.58
EXEL's P/S is ranked lower than
76% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. EXEL: 35.58 )
Ranked among companies with meaningful P/S only.
EXEL' s 10-Year P/S Range
Min: 1.65  Med: 8.02 Max: 50.5
Current: 35.58
1.65
50.5
Current Ratio 1.52
EXEL's Current Ratio is ranked lower than
80% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. EXEL: 1.52 )
Ranked among companies with meaningful Current Ratio only.
EXEL' s 10-Year Current Ratio Range
Min: 0.84  Med: 2.36 Max: 9.35
Current: 1.52
0.84
9.35
Quick Ratio 1.48
EXEL's Quick Ratio is ranked lower than
76% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. EXEL: 1.48 )
Ranked among companies with meaningful Quick Ratio only.
EXEL' s 10-Year Quick Ratio Range
Min: 0.84  Med: 2.36 Max: 9.35
Current: 1.48
0.84
9.35
Days Inventory 390.30
EXEL's Days Inventory is ranked lower than
91% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 122.55 vs. EXEL: 390.30 )
Ranked among companies with meaningful Days Inventory only.
EXEL' s 10-Year Days Inventory Range
Min: 35.45  Med: 470.86 Max: 471.76
Current: 390.3
35.45
471.76
Days Sales Outstanding 44.21
EXEL's Days Sales Outstanding is ranked higher than
66% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. EXEL: 44.21 )
Ranked among companies with meaningful Days Sales Outstanding only.
EXEL' s 10-Year Days Sales Outstanding Range
Min: 4.51  Med: 27.96 Max: 82.11
Current: 44.21
4.51
82.11

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 4.41
EXEL's Price/Median PS Value is ranked lower than
92% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. EXEL: 4.41 )
Ranked among companies with meaningful Price/Median PS Value only.
EXEL' s 10-Year Price/Median PS Value Range
Min: 0.25  Med: 1.12 Max: 4.79
Current: 4.41
0.25
4.79
Earnings Yield (Greenblatt) (%) -9.54
EXEL's Earnings Yield (Greenblatt) (%) is ranked lower than
58% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. EXEL: -9.54 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
EXEL' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -9.64  Med: 11.90 Max: 16.4
Current: -9.54
-9.64
16.4

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 67 105
EPS($) -0.81 -0.79
EPS without NRI($) -0.81 -0.79

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:EX9.Germany,
Exelixis Inc incorporated in November, 1994. It is a biotechnology company which develops small molecule therapies to treat cancer. Its two advanced assets, COMETRIQ "cabozantinib", its wholly-owned inhibitor of multiple receptor tyrosine kinases, and cobimetinib "GDC-0973/XL518", a potent, highly selective inhibitor of MEK, which it out-licensed to Genentech, Inc. a wholly-owned member of the Roche Group, or Genentech, are currently the subject of six ongoing phase 3 pivotal trials. Cabozantinib is being evaluated in a development program, including two ongoing phase 3 pivotal trials in metastatic castration-resistant prostate cancer or CRPC, an ongoing phase 3 pivotal trial in metastatic renal cell cancer or RCC, and an ongoing phase 3 pivotal trial in advanced hepatocellular cancer, or HCC. The programs that the Company runs are Cabozantinib Development Program, CRPC, COMET Pivotal Trials, Combination trials. The Company has development programs in collaboration with Genentech, GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, Daiichi Sankyo Company Limited. It contracts third parties to manufacture raw materials, the active pharmaceutical ingredient, or API, and finished solid dose COMETRIQ products for clinical and commercial uses. The Company follows regulations set forth by FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries. Federal and state healthcare laws, including fraud and abuse and health information privacy and security laws, are applicable to the Company.
» More Articles for EXEL

Headlines

Articles On GuruFocus.com
5-year lows: Synta Pharmaceuticals Inc, Exelixis Inc, Entropic Communications Inc, and Aeropostale I Dec 28 2014 
5-year lows: National Presto Industries, Ennis Inc, Landauer Inc, and Exelixis Inc. Sep 28 2014 
Weekly 3-Year Low Highlights: UAN, CLD, EXEL, QNST Sep 06 2014 
Five-Year Lows: Rentech Nitrogen Partners LP, SandRidge Permian Trust, Millennial Media Inc., Exelix May 05 2014 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
Exelixis Inc. Reports Operating Results (10-K) Feb 22 2011 
Exelixis Inc. (EXEL) CFO Frank Karbe buys 16,500 Shares Aug 25 2010 
Exelixis Inc. Reports Operating Results (10-Q) Aug 05 2010 
Exelixis Inc. Reports Operating Results (10-Q) May 11 2010 
Exelixis Announces Second Quarter 2009 Financial Results Jul 30 2009 

More From Other Websites
Exelixis Up on Swiss Approval of Advanced Melanoma Drug Aug 28 2015
Did Hedge Funds Sell Out Of Exelixis, Inc. (EXEL) Too Soon? Shares Jump On Regulatory Approval of... Aug 27 2015
Exelixis (EXEL) Stock Climbs as Melanoma Treatment Gets Swiss Regulatory Approval Aug 27 2015
Exelixis Announces First Regulatory Approval of Cobimetinib in Switzerland Aug 27 2015
Exelixis Announces First Regulatory Approval of Cobimetinib in Switzerland Aug 27 2015
Exelixis' Cancer Drug Gets Breakthrough Therapy Status Aug 25 2015
EXELIXIS, INC. Financials Aug 25 2015
FDA Grants Breakthrough Therapy Designation to Exelixis’ Cabozantinib for the Treatment of Renal... Aug 24 2015
Data From METEOR Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma Accepted as... Aug 24 2015
Data From METEOR Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma Accepted as... Aug 24 2015
FDA Grants Breakthrough Therapy Designation to Exelixis’ Cabozantinib for the Treatment of Renal... Aug 24 2015
Make Room for Exelixis in Your Portfolio Aug 12 2015
Exelixis Posts Wider-Than-Expected Loss, Focus on Pipeline Aug 12 2015
Edited Transcript of EXEL earnings conference call or presentation 11-Aug-15 9:00pm GMT Aug 12 2015
Exelixis Inc Earnings Call scheduled for 5:00 pm ET today Aug 11 2015
Exelixis reports 2Q loss Aug 11 2015
Exelixis reports 2Q loss Aug 11 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK